The Directorate of Pharmacy and Drugs of the Ministry of Health (Minsa) indicates how it is public knowledge, through Law 242 of October 13, 2021, the medicinal and therapeutic use of cannabis and its derivatives was regulated.
In it, it is established that the License for the Manufacture of Medicinal Cannabis Derivatives allows the import, export, commercialization, manufacture and sanitary registration for therapeutic, medical, scientific and research use.
Through a statement, it is reported that they are currently in the selection process to grant the License for the Manufacture of Medicinal Cannabis derivatives, for which reason the general public is informed that cannabis derivative products are not currently authorized in the Republic of Panama, for distribution and sale.
In accordance with the provisions of the Regulation, in the Panamanian territory, the import, export, commercialization, manufacture and sanitary registration of cannabis derivatives for therapeutic, medical, scientific and research uses will only be allowed to Licensees authorized by the Ministry of Health, through the National Directorate of Pharmacy and Drugs.
Similarly, the aforementioned Law states in its article 79, that any use or handling of cannabis or its derivatives that is not established in Law 242 of 2021, will be sanctioned as provided in the Penal Code.
